Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.

Intervention(s) in this Clinical Trial

• Drug: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
  • 1 drop in eye(s) every evening

Arms, Groups and Cohorts in this Clinical Trial

• : 1
  • bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%

Primary Measures

• Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year
  • Time Frame: Baseline, 1 Year
    Safety Issue?: No

Inclusion Criteria:

• A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR presenting with insufficiently controlled IOP on current medication (in the opinion of the treating physician)
• Patient is having both eyes treated

Exclusion Criteria:

• Contraindications per product labelling will apply.
• Patients with any ophthalmic co-morbidity with an influence on visual field deterioration or optic nerve head damage.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Allergan Industry

Overall Clinical Trial Officials and Contacts

Medical Director Study Director Allergan  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00716742

Study ID Number: Pro2

ClinicalTrials.gov Identifier: NCT00716742

Health Authority: United States: Institutional Review Board